Plain-English translation of NCT07349472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help treat ulcerative colitis—a long-term condition that causes inflammation and bleeding in the colon. You would take the medication twice daily alongside , a standard treatment for this condition. The study wants to see if this medication can reduce symptoms and improve quality of life compared to a placebo.
Ulcerative colitis can be difficult to manage, and doctors are looking for new ways to reduce inflammation and give patients better relief from painful symptoms. This trial is testing whether this medication might be a safe and effective addition to current treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive the new medication twice daily or a placebo twice daily—both taken alongside , which you may already be using. You will take your assigned treatment at home and visit the clinic for check-ups to see how well the treatment is working and to monitor for any side effects. The exact duration and number of visits will be explained when you enroll.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Egypt
Sponsor
Ihab Elsayed Hassan
Enrollment target
~60 participants
Started
January 2026
Primary completion
January 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.